Regatta Capital Group LLC Has $759,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Regatta Capital Group LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 919 shares of the company’s stock after acquiring an additional 20 shares during the quarter. Regatta Capital Group LLC’s holdings in Eli Lilly and Company were worth $759,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company in the fourth quarter valued at $43,000. FPC Investment Advisory Inc. increased its holdings in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after purchasing an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $48,000. Compass Financial Services Inc bought a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $50,000. Finally, Capital A Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $63,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on LLY. Guggenheim reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. HSBC downgraded Eli Lilly and Company from a “buy” rating to a “reduce” rating and dropped their price target for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Hsbc Global Res downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,011.37.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $773.59 on Tuesday. The company has a market cap of $733.16 billion, a price-to-earnings ratio of 66.06, a P/E/G ratio of 1.40 and a beta of 0.40. The business’s fifty day simple moving average is $769.95 and its two-hundred day simple moving average is $800.81. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Eli Lilly and Company’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.58 earnings per share. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.78%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.